Board of Directors
Axel Bolte, MSc., M.B.A.
Investment Advisor, HBM Healthcare Investments AG
He currently serves or has served on the board of directors of various private and public biotechnology companies, including Adnexus Therapeutics (acquired by BMS), Kolltan Pharmaceuticals, Nabriva Therapeutics, Newron Pharmaceuticals, and PTC Therapeutics.
Mr. Bolte studied biochemistry and organic chemistry at the University of Cambridge, United Kingdom and the Swiss Federal Institute of Technology in Zurich, Switzerland, where he obtained an M.S. in biochemistry. He also obtained an MBA from the University of St. Gallen, Switzerland.
Thomas Dyrberg, M.D., DMSc.
Senior Partner, Novo Ventures and Novo A/S
Nordisk A/S in health care discovery and clinical drug development.
He currently serves or has served on the board of directors of several biotechnology companies, including Veloxis Pharmaceuticals A/S, Gloucester Pharmaceuticals, Inc., Allocure Inc., Lux Biosciences, Inc., Sapphire Therapeutics Inc., Delenex Therapeutics AG, and BioMimetic Therapeutics, Inc.
Dr. Dyrberg received his M.D. degree from the University of Copenhagen in 1981 and his Doctor of Medical Science (D.M.Sc.) degree, also from the University of Copenhagen, in 1986.
David R. Guyer, M.D.
Chief Executive Officer, Ophthotech Corporation (Executive Chairman, effective July 1, 2017)
Following a successful career in academic medicine as Professor and Chairman of the Department of Ophthalmology at New York University School of Medicine, Dr. Guyer co-founded and served as CEO and Director at Eyetech Pharmaceuticals, Inc., where he led the company through private, public and corporate financings over $400 million, and oversaw the rapid development and successful commercialization of Macugen® (pegaptanib sodium), the first FDA-approved anti-VEGF pharmacological treatment for wet AMD. Under his leadership, Eyetech reached a peak market capitalization of approximately $2 billion.
Dr. Guyer received his Bachelor of Science (B.S.) degree from Yale College summa cum laude and his medical degree (M.D.) from Johns Hopkins Medical School. He completed his ophthalmology residency at Wilmer Ophthalmological Institute at Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.
Former Partner, Wilmer Cutler Pickering Hale and Dorr LLP
Mike Ross, Ph.D.
Managing Partner, SV Life Sciences
Dr. Ross currently serves or has served on the board of directors of several biotechnology companies, including Aderis Pharmaceuticals, Adimab, Alinea, Archemix, Arris Pharmaceuticals, Arsanis, Carta Proteomics, CyThera, Glycofi, Epimmune, Genencor, Ikano, Itero Biopharmaceuticals, Link Medicine, MetaXen, Mpex, NKT Therapeutics, Rempex, Rinat, Sutro Biopharmaceuticals and Xenova. He also serves on the board of directors of Thayer School of Engineering at Dartmouth College.
Dr. Ross received his Bachelor of Arts (B.A.) from Dartmouth College, his Doctor of Philosophy (Ph.D.) degree in Chemistry from the California Institute of Technology (Caltech), and completed a Post-Doctorate program in Molecular Biology at Harvard University.
Ian F. Smith
Executive Vice President and Chief Financial Officer, Vertex Pharmaceuticals
Mr. Smith currently serves as a member of the Board of Directors of both Acorda Therapeutics and Infinity Pharmaceuticals, and chairs each company’s audit committee.
Mr. Smith studied at Manchester Metropolitan University, United Kingdom, where he obtained a B.A. with honors in accounting and finance. He is a current member of the Institute of Chartered Accountants of England and Wales.